Abstract

ObjectiveEndothelial dysfunction is central to the pathogenesis of many rheumatic diseases, typified by vascular inflammation and damage. Immunosuppressive drugs induce disease remission and lead to improved patient survival. However, there remains a higher incidence of cardiovascular disease in these patients even after adequate disease control. The purpose of this study was to determine the effect of mycophenolic acid (MPA), a commonly used immunosuppressive drug in rheumatology, on blood vessel or circulating endothelial colony forming cell number and function.MethodsWe tested whether mycophenolic acid exerts an inhibitory effect on proliferation, clonogenic potential and vasculogenic function of endothelial colony forming cell. We also studied potential mechanisms involved in the observed effects.ResultsTreatment with MPA decreased endothelial colony forming cell proliferation, clonogenic potential and vasculogenic function in a dose-dependent fashion. MPA increased senescence-associated β-galactosidase expression, p21 gene expression and p53 phosphorylation, indicative of activation of cellular senescence. Exogenous guanosine supplementation rescued diminished endothelial colony forming cell proliferation and indices of senescence, consistent with the known mechanism of action of MPA.ConclusionOur findings show that clinically relevant doses of MPA have potent anti-angiogenic and pro-senescent effects on vascular precursor cells in vitro, thus indicating that treatment with MPA can potentially affect vascular repair and regeneration. This warrants further studies in vivo to determine how MPA therapy contributes to vascular dysfunction and increased cardiovascular disease seen in patients with inflammatory rheumatic disease.

Highlights

  • Chronic inflammatory rheumatic disease (CIRD) is a heterogeneous group of complex, multisystem disorders characterized by the presence of chronic local or systemic inflammation [1]

  • Our findings show that clinically relevant doses of Mycophenolic acid (MPA) have potent anti-angiogenic and pro-senescent effects on vascular precursor cells in vitro, indicating that treatment with MPA can potentially affect vascular repair and regeneration

  • This warrants further studies in vivo to determine how MPA therapy contributes to vascular dysfunction and increased cardiovascular disease seen in patients with inflammatory rheumatic disease

Read more

Summary

Introduction

Chronic inflammatory rheumatic disease (CIRD) is a heterogeneous group of complex, multisystem disorders characterized by the presence of chronic local or systemic inflammation [1]. CIRD can lead to severe and often life-threatening complications in patients and death if untreated [2,3,4]. Immunosuppressive agents are the mainstay of therapy and have tremendously improved the outcomes of CIRD patients [8, 9]. Mycophenolic acid (MPA), an inosine monophosphate dehydrogenase (IMPDH) enzyme inhibitor and the active metabolite of mycophenolate mofetil, is an immune suppressive drug that is widely used in treating patients with systemic rheumatic diseases. MPA inhibits guanine nucleotide synthesis that is essential to the survival of lymphocytes known to be involved in the immune response in CIRD [10]. MPA has been reported to restrict proliferation of non-lymphoid cells [11,12,13]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call